Pfizer's Active Layer: Fisher Asset Mgmt Holds PFE at 4x Index

Pfizer has been the most-shorted mega-cap pharma name through 2024-2026 as the company's post-COVID revenue cliff (Comirnaty plus Paxlovid combined declined from $57 billion peak in 2022 to under $10 billion by 2025) plus a delayed pipeline yields a multi-year operational restructuring story. The institutional positioning reflects the bear case: most active managers run PFE at near-index or underweight. One name breaks the pattern: Fisher Asset Management holds $2.95 billion of Pfizer at exactly 1.00% portfolio weight — roughly 4x the S&P 500 index weight of approximately 0.25%. Ken Fisher's deep-value discipline bet on PFE is the cleanest active conviction signal in the book.

Pfizer's 3,136 institutional holders read mostly as passive index inventory plus modest active positioning. The standout exceptions are Fisher's 1.00% portfolio bet and a handful of smaller value-disciplined holders. The combination produces an unusual holder shape: deep retail-sentiment underweight, deep index-weight passive support, and concentrated discretionary bet at a single value-focused active manager.

The Pfizer reset context

Pfizer's revenue trajectory tells the bear-case story directly:

• 2022 peak revenue: $100 billion (driven by $57 billion Comirnaty + Paxlovid combined)
• 2024 revenue: ~$58 billion (-42% from peak)
• 2025 revenue: ~$63 billion (modest recovery as base business stabilized)
• 2026 guidance: $61-64 billion range

The replacement-pipeline question is the central operational debate. Pfizer's post-COVID acquisitions — Seagen ($43 billion in 2023 for the antibody-drug conjugate platform), GBT (sickle-cell franchise), Trillium (oncology) — represent $50+ billion of M&A capex that must convert into operational revenue. The market has been skeptical, producing PFE's multi-year multiple compression from a 14x peak forward P/E in 2022 to 8-9x forward P/E in late 2025.

The 3,136-institution holder book

Pfizer's holder structure carries the standard passive index sleeve plus a few notable active positions:

• BlackRock: $13.99 billion, 0.24% portfolio — near-index weight versus PFE's S&P 500 weight of ~0.25%.
• Vanguard Capital Management: $10.37 billion, 0.26% portfolio.
• State Street: $7.48 billion, 0.25% portfolio.
• Vanguard Portfolio Management: $3.28 billion, 0.17% portfolio.
• Geode Capital (passive_index): $3.24 billion, 0.20% portfolio.
• Fisher Asset Management: $2.95 billion, 1.00% portfolio — 4x index overweight.
• Morgan Stanley: $2.22 billion, 0.13% portfolio.
• Northern Trust (passive_index): $1.74 billion, 0.23% portfolio.

Fisher's value-discipline bet

Fisher Asset Management LLC is the personal-account asset-management arm of Ken Fisher, running $294.89 billion across active equity strategies with explicit value-and-quality factor tilts. The 1.00% PFE portfolio weight at 4x index reflects Fisher's view that:

1. Pfizer's multiple has overcorrected for the COVID revenue cliff. At 8-9x forward P/E, PFE trades below the broader pharma sector multiple of 13-15x — a value-screen signal.
2. The Seagen acquisition will eventually convert. Antibody-drug conjugates (ADCs) are one of the fastest-growing oncology drug categories. Pfizer-Seagen's pipeline includes multiple Phase 3 readouts through 2026-2027.
3. Dividend yield supports the position. PFE's 6%+ dividend yield at the current depressed multiple is one of the highest in big pharma. Fisher's strategy weights dividend yield prominently in its quality screens.

Fisher has held the position through the 2024 multiple compression and the partial 2025-2026 recovery. The 1.00% portfolio weight has been steady across multiple quarters, suggesting the position is structural rather than tactical.

The other 2-3% active conviction layer

Beyond Fisher, the active conviction at PFE is concentrated at a few value-discipline managers:

• Wellington Management Group: small-to-moderate overweight, typically 0.3-0.5% portfolio.
• Various dividend-focused active vehicles run PFE at 0.5-1.0% portfolio because the 6%+ yield meets income-mandate criteria.

The combined active-conviction layer outside Fisher is thin. Most large active managers (Capital Group, Wellington, Fidelity) run PFE at slight overweight to slight underweight versus index — they do not have Fisher's 4x conviction.

What's absent

Three observations:

1. No Berkshire position. Buffett held a small PFE stake during COVID that was exited; current Berkshire pharma exposure is minimal.
2. No activist 13D filings. Despite the multi-year revenue cliff and capital-allocation criticism on Seagen pricing, no external activist has filed against Pfizer.
3. Limited Capital Group position. Capital World Investors and Capital Research Global Investors are not in PFE's top 10. The Capital Group complex appears to discount the post-COVID-cliff recovery thesis more than Fisher does.

What to track

1. Pfizer Q2 2026 earnings (early August). Seagen-integrated revenue contribution, base-business excluding COVID products, and 2026 guidance will determine whether the multiple expansion thesis continues.
2. Fisher's Q2 2026 13F (due August 14, 2026). Whether the 1.00% portfolio weight on PFE holds, expands, or trims is the cleanest signal of value-discipline view shift. Track via the institutional signals feed.
3. ADC pipeline data. Tisotumab vedotin (Tivdak), other Seagen-acquired ADCs, and Pfizer internal ADC programs have Phase 3 readouts through 2026-2027. Each binary event affects the post-Keytruda oncology narrative.
4. Dividend coverage. Pfizer's 6%+ yield is supported by current cash flow but compresses if 2026 revenue falls below the $58-62 billion range. Watch the cash-flow coverage ratio quarterly.

Pfizer's holder book carries the cleanest value-discipline active conviction at Fisher Asset Management's 1.00% portfolio bet. The 4x index overweight is a structural call on multiple expansion through Seagen integration and dividend-yield-supported equity. For more on identifying single-fund-family value-discipline conviction across multiple cycles, see our explainer hub.

Source: SEC Form 13F-HR filings for Q1 2026 period ending 2026-03-31, accession listings at Pfizer Inc. SEC filer index.